• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Novartis AG Common Stock (NY:NVS)

143.11 -0.17 (-0.12%)
Official Closing Price Updated: 4:10 PM EDT, Oct 8, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,532,574
Open 142.77
Bid (Size) 138.58 (100)
Ask (Size) 144.28 (10,000)
Prev. Close 143.28
Today's Range 140.68 - 143.29
52wk Range 121.57 - 170.46
Shares Outstanding N/A
Dividend Yield 3.34%
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novartis AG - NVS
October 06, 2026
From Pomerantz LLP
Via GlobeNewswire
News headline image
Royalty Pharma Owns a Piece of 16 Blockbuster Drugs -- Is the Stock a Buy? ↗
October 01, 2026
Investors are catching on to this rare gem among pharmaceutical stocks, but thanks to promising growth and a low valuation, further upside remains. 
Via The Motley Fool

Performance

52-Week Range 16.0% below 52-week high
143.11
121.5752W Low 170.4652W High
1 Week 0.8% below 1-week high
139.311W Low 144.281W High

Novartis AG Common Stock (NVS) traded between $121.57 and $170.46 over the past 52 weeks and last traded at $143.11, 16.0% below its 52-week high. Over the past week it ranged between $139.31 and $144.28.

Past 12 Months
+1.5%
+3.9%
-7.8%
-7.3%
+3.3%
+8.8%
1W +$2.06
1M +$5.41
3M -$12.06
6M -$11.31
YTD +$4.57
1Y +$11.56

NVS was +8.8% over the past year, -7.3% over six months, +3.3% year to date, +1.5% in the last week.

12 Months vs Market
NVS
+8.8%
DIA
+9.8%
SPY
+15.7%
QQQ
+23.7%
IWM
+13.7%

Over the past 12 months NVS returned +8.8% versus DIA (Dow) +9.8%, SPY (S&P 500) +15.7%, QQQ (Nasdaq 100) +23.7% and IWM (Russell 2000) +13.7%.

Volume & Liquidity 0.78× 3-mo avg
Today 1,532,574 3-mo avg 2.0M
1W
1.8M
1M
2.4M
3M
2.0M
6M
1.8M
YTD
2.0M
1Y
1.9M

NVS most recently traded 1,532,574 shares against a 3-month average daily volume of 2.0M.

More News

Read More
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novartis AG - NVS
September 29, 2026
From Pomerantz LLP
Via GlobeNewswire
News headline image
At the Longevity Investors Conference in Gstaad, Investors Test Which Longevity Claims Hold Up
September 29, 2026
Via Newsfile
Novartis (NYSE:NVS) Offers Dividend Investors a Quality Income Profile ↗
September 26, 2026
Via Chartmill
News headline image
Leaders Face Stark Warning from Silicon Valley Veteran – The Old Way of Working is Dead
September 25, 2026
Via Get News
Topics Artificial Intelligence
News headline image
Where Will CRISPR Therapeutics Be in 10 Years if Gene Editing Fulfills Its Promise? ↗
September 17, 2026
Via The Motley Fool
News headline image
Worried About a Market Crash? This Dividend Stock Outperformed as the S&P 500 Sank in Both 2008 and 2022 ↗
September 16, 2026
Via The Motley Fool
Topics Economy Intellectual Property Stocks
News headline image
Novartis Suffers Another Setback After Two High-Profile Surprises Hammered Shares ↗
September 16, 2026
Via Investor's Business Daily
News headline image
VanEck Pharmaceutical ETF vs VanEck Biotech ETF: Which Fund Is Better for Drug Innovation Profits? ↗
September 15, 2026
Via The Motley Fool
Topics ETFs
News headline image
Novartis Just Shook Up a Multibillion-Dollar Drug Race. What It Means for Eli Lilly Stock. ↗
September 14, 2026
Via The Motley Fool
News headline image
Amgen Drops 10% on a Trial It Didn't Even Run ↗
September 11, 2026
Via MarketBeat
News headline image
Top Investor Urges Novartis for Stronger Acquisition Oversight After M&A and Trial Setbacks ↗
September 11, 2026
Via Benzinga
MissionIRNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Advances Lucid-MS Toward Phase 2 Trial Following FDA Clearance
September 10, 2026
Via Investor Brand Network
Historic First in MS Treatment Could Reshape a Multibillion-Dollar Therapeutics Market
September 10, 2026
Via Investor Brand Network
MissionIRNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Advances Lucid-MS Toward Phase 2 Trial Following FDA Clearance
September 10, 2026
Via Investor Brand Network
News headline image
Historic First in MS Treatment Could Reshape a Multibillion-Dollar Therapeutics Market
September 10, 2026
From BioMedWire
Via GlobeNewswire
News headline image
2025 R&D Spending And Intensity Benchmarks
September 09, 2026
Via PRLog
Topics Supply Chain
News headline image
Stock Market Today, Sept. 8: Stocks Slide Amid Surging Oil Prices, Persistent Geopolotical Tenisons ↗
September 08, 2026
Via The Motley Fool
Topics Artificial Intelligence Stocks World Trade
News headline image
A Rivals Clinical Stumble Sends Sarepta Therapeutics Stock Lower ↗
September 08, 2026
Via Benzinga
News headline image
Novartis Myotonic Dystrophy Trial Flop Sends Dyne Therapeutics Shares Tumbling ↗
September 08, 2026
Via Benzinga
News headline image
How Novartis And Ionis' High-Profile Failure Reverberated Through Biopharma ↗
September 08, 2026
Via Investor's Business Daily
News headline image
Novartis, Ionis Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session ↗
September 08, 2026
Via Benzinga
News headline image
Novartis Stock Drops as Trial Failures Ripple Across Biotech Partners ↗
September 08, 2026
Via Benzinga
News headline image
United Natural Foods, ABM Industries and 3 Stocks to Watch Heading Into Tuesday ↗
September 08, 2026
Via Benzinga

Frequently Asked Questions

Is Novartis AG Common Stock publicly traded?
Yes, Novartis AG Common Stock is publicly traded.
What exchange does Novartis AG Common Stock trade on?
Novartis AG Common Stock trades on the New York Stock Exchange
What is the ticker symbol for Novartis AG Common Stock?
The ticker symbol for Novartis AG Common Stock is NVS on the New York Stock Exchange
What is the current price of Novartis AG Common Stock?
The current price of Novartis AG Common Stock is 143.11
When was Novartis AG Common Stock last traded?
The last trade of Novartis AG Common Stock was at 10/08/26 04:10 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap